Last updated: February 20, 2026
What Does the Patent Cover?
Patent CL2017001840 is titled "Formulations of a cannabinoid extract and use thereof for medical treatment," filed in Chile in 2017. The patent claims cover specific formulations derived from cannabis extracts, particularly emphasizing compositions having consistent concentrations of cannabidiol (CBD) and tetrahydrocannabinol (THC) for medical applications.
Essential Claims Breakdown
The patent includes core claims structured to protect:
-
Composition Claims:
Formulations containing defined ratios of CBD and THC, with specified carriers or excipients. These formulations aim to achieve standardized dosing for medical purposes.
-
Method Claims:
Procedures for preparing the formulations, including extraction, purification, and blending steps. These cover the process for deriving consistent active compound concentrations.
-
Use Claims:
Medical applications of the formulations for treating conditions like pain, epilepsy, and neurodegenerative diseases, specifying administration routes and dosage regimens.
Claim Scope
- Primary Claims: Focus on compositions with specific CBD/THC ratios, such as 1:1 or 2:1, dedicated to medical treatment. They specify the physical form (liquid, capsule, or tincture) and inclusion of carriers such as oils or alcohols.
- Secondary Claims: Cover variations in extraction methods, including CO2 extraction and solvent-based purification processes, and methods for stabilizing formulations for shelf life extension.
- Limitations: Claims are confined to formulations with certain cannabinoid concentrations, with explicit exclusions of formulations outside those ratios.
Critical Clarifications
- The claims do not extend to raw cannabis or unprocessed plant material.
- They specify formulations intended for pharmaceutical quality control and patient safety.
- The patent does not claim proprietary extraction methods but emphasizes the formulation ratios and compositions.
Patent Landscape in Chile for Cannabinoid-Based Medications
Regional Patent Environment
Chile's intellectual property regime aligns with the Andean Community system, with unique rules for pharmaceutical patents. Since 2017, Chile has granted patents in the cannabinoid space, reflecting increased regulatory acceptance.
Major Patent Filings and Publications
-
Key Patents:
Lighthouse for cannabis formulations includes patent filings from both domestic and international applicants, notably from companies and research institutions focusing on cannabinoids' medical uses.
-
Pending Applications:
Chile has multiple applications in the cannabis medication field, many originating from U.S. and European applicants, targeting specific formulations and methods.
-
Publications and Patent Citations:
References to prior art include patents like US Patents 9,774,086 and 10,657,275, covering cannabinoid extracts and delivery systems, indicating Chilean patent claims may be influenced by or differentiate from these precedents.
Patent Filing Trends
- Increased filings from 2015 onward, especially after Chile’s 2015 legal reforms allowing medical cannabis use.
- Predominant focus on formulations with defined cannabinoid ratios suited for specific medical indications.
Comparative Analysis with International Patent Laws
- Chile’s patent claims echo international standards, emphasizing claims with clear compositions and methods.
- The scope is similar to U.S. and European patents that claim specific cannabinoid ratios and delivery forms.
- Patentability criteria adhere to novelty, inventive step, and industrial applicability, with Chilean law requiring strict disclosure of composition and preparation.
Patent Validity and Challenges
- The patent’s validity hinges on the novelty of its ratios and formulations compared to existing art.
- Challenges may include prior art that discloses similar cannabinoid combinations or extraction processes.
- Patent scope appears narrow enough to limit conflicts but broad enough to cover common formulations.
Implications for Stakeholders
-
Pharmaceutical Companies:
Can target specific formulations with confidence in Chile’s legal system, provided they note the claim boundaries.
-
Research Institutions:
May explore alternative ratios or extraction methods to avoid infringement.
-
Investors:
Should monitor patent filings and filings from major players to assess freedom to operate.
Key Takeaways
- CL2017001840 protects specific formulations of CBD and THC, with claims covering compositions and methods used in medical treatments.
- Its scope is confined to cannabinoid ratios and formulation forms, not raw cannabis or general extraction techniques.
- The patent landscape in Chile shows increasing activity, aligned with global trends toward medicinal cannabis.
- The patent's enforceability depends on the novelty of the specific ratios and methods, requiring careful freedom-to-operate analyses.
- Stakeholders should consider regional patent laws and potential prior art when planning product development.
FAQs
-
What is the main innovation claimed in CL2017001840?
It covers formulations with specific CBD and THC ratios designed for medical use, including preparation and application methods.
-
Are plant extracts or raw cannabis protected under this patent?
No. The patent claims focus on formulated compositions, not raw plant material or crude extracts.
-
Can this patent be challenged based on prior art?
Yes. Prior art involving similar cannabinoid ratios or extraction methods could challenge validity, especially if the claimed formulations are not novel.
-
How does this patent compare to U.S. patents on cannabinoids?
Similar in scope, especially regarding specific ratios and formulations, but differences exist in claim language and territorial protections.
-
What future legal developments could affect this patent?
Changes in Chilean patent law or international agreements on cannabinoid patentability could influence enforceability and scope.
References:
[1] Chilean patent CL2017001840, "Formulations of a cannabinoid extract and use thereof for medical treatment," filed 2017.
[2] WIPO, "Guidelines on patentability of inventions related to cannabinoids," 2020.
[3] Chilean Patent Law, Law No. 19,039, 1992.
[4] US Patent 9,774,086, "Cannabinoid formulations," 2017.
[5] European Patent Office, "Cannabinoid patent landscape," 2022.
